https://scholars.lib.ntu.edu.tw/handle/123456789/541066
標題: | Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer | 作者: | JYH-MING LIOU CHIA-TUNG SHUN JIN-TUNG LIANG HAN-MO CHIU MEI-JYH CHEN CHIEN-CHUAN CHEN HSIU-PO WANG MING-SHIANG WU Lin J.-T. |
公開日期: | 2010 | 出版社: | Endocrine Society | 卷: | 95 | 期: | 4 | 起(迄)頁: | 1717-1725 | 來源出版物: | Journal of Clinical Endocrinology and Metabolism | 摘要: | Context: Overexpression of IGF-II and IGF-binding protein (IGFBP)-2 has been reported in several cancers. Objective: We aimed to assess the roles of plasma IGF-II and IGFBP-2 levels as diagnostic and prognostic biomarkers and the impact of loss of imprinting (LOI) of IGF-II on the survival of colorectal cancer (CRC). Design: We conducted a case control and prospective cohort study for diagnostic and prognostic values, respectively. Patients and Setting: Plasma levels of IGF-II and IGFBP-2 were measured in 162 patients with CRC before surgery, in paired 15 patients after curative surgery, in 24 patients with advanced colon polyps, and in 114 healthy controls between 2003 and 2006 in National Taiwan University Hospital. Results: The area under the curve values of using IGFBP-2 as a diagnostic marker for advanced colon polyp and CRC were 0.654 [95% confidence interval (CI) = 0.547-0.76; P = 0.017] and 0.815 (95% CI = 0.766-0.864; P < 0.001), respectively. The sensitivity and specificity for diagnosing CRC were 80.2 and 64%, respectively, if the cutoff value of IGFBP-2 was 377 ng/ml. In the multivariate Cox proportional hazards regression model, higher IGFBP-2 levels were associated with increased risk of mortality [hazard ratio (HR) = 2.46; P = 0.017], whereas higher IGF-II levels were associated with reduced risk of mortality (HR = 0.42; P = 0.044). LOI of IGF-II was associated with increased risk of mortality (HR = 7.91; P = 0.014) in patients with stage IV disease. Conclusions: IGFBP-2 is a potential diagnostic and prognostic biomarker of CRC. LOI of IGF-II is significantly associated with poor prognosis in patients with stage IV disease. Copyright ? 2010 by The Endocrine Society. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-77951641606&doi=10.1210%2fjc.2009-2668&partnerID=40&md5=24e34cda35c2681ae85ca56dad132970 https://scholars.lib.ntu.edu.tw/handle/123456789/541066 |
ISSN: | 0021-972X | DOI: | 10.1210/jc.2009-2668 | SDG/關鍵字: | somatomedin B; somatomedin binding protein 2; DNA; RNA; somatomedin B; somatomedin binding protein 2; tumor marker; adult; advanced cancer; article; cancer diagnosis; cancer mortality; cancer risk; cancer surgery; cancer survival; colon polyp; colorectal cancer; controlled study; female; human; major clinical study; male; priority journal; prognosis; prospective payment; protein blood level; sensitivity and specificity; university hospital; aged; biosynthesis; blood; colon polyp; colorectal tumor; disease course; genetics; genome imprinting; Kaplan Meier method; metabolism; middle aged; prognosis; proportional hazards model; risk assessment; survival; treatment outcome; Aged; Colonic Polyps; Colorectal Neoplasms; Disease Progression; DNA; Female; Genomic Imprinting; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor II; Kaplan-Meiers Estimate; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Assessment; RNA; Survival Analysis; Treatment Outcome; Tumor Markers, Biological |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。